Not independent
Tenure on this board
1.1 yrs
Meeting calendar
OMDA · Annual meeting · Tuesday, June 16, 2026
Omada Health Inc
2 nominees · 3 ballot items.
Elect two Class I directors (Sean Duffy and Trevor Fetter) and ratify Deloitte & Touche LLP as the Company’s independent registered public accounting firm for 2026; also consider any other properly presented business.
Market cap
$1.4B
1Y TSR
+17.4%
Board grade
C-
Record date
Apr 20, 2026
Filing
DEF 14A
Meeting concluded · Jun 16, 2026
Follow how the vote landed and what changed on Omada Health Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors — Sean Duffy and Trevor Fetter as Class I Directors
ManagementBoard: FORElect Sean Duffy and Trevor Fetter as Class I Directors to serve until the 2029 Annual Meeting of Stockholders and until their successors are elected and qualified.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Deloitte & Touche LLP as Omada Health’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
- 3
Other business
ManagementTo transact such other business as may properly come before the Annual Meeting or any continuation, postponement, or adjournment.
Director elections
Nominees on the ballot2
Independent
Tenure on this board
1.1 yrs
Also a director at
Hartford Insurance Group Inc (HIG)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Divisadero Street Capital Management, LP | 9.9% | 5,887,715 | $74M |
| 2 | Revelation Capital Management, LLC | 8.8% | 5,208,034 | $65M |
| 3 | CIGNA INVESTMENTS INC /NEW | 5.8% | 3,444,629 | $43M |
| 4 | NVP Associates, LLC | 4.3% | 2,531,000 | $32M |
| 5 | AMERICAN CENTURY COMPANIES INC | 4.1% | 2,456,309 | $31M |
| 6 | a16z Capital Management, L.L.C. | 3.9% | 2,307,284 | $29M |
| 7 | FMR LLC | 3.4% | 2,014,391 | $25M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 3.0% | 1,808,984 | $23M |
| 9 | LOOMIS SAYLES CO L P | 2.4% | 1,440,346 | $18M |
| 10 | MORGAN STANLEY | 2.2% | 1,285,386 | $16M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Omada Health Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Reference
Frequently asked questions
- When is the Omada Health Inc 2026 annual meeting?
- Omada Health Inc (OMDA) holds its 2026 annual shareholder meeting on Tuesday, June 16, 2026.
- What is the record date for the Omada Health Inc 2026 meeting?
- The record date for the Omada Health Inc 2026 meeting is Monday, April 20, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Omada Health Inc's 2026 meeting?
- The board is presenting 2 director nominees at the Omada Health Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Omada Health Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Omada Health Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.